# 10x Genomics, Inc. – Consensus ‘buy’ rating and 34.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc-consensus-buy-rating-and-34-0-upside-potential/4121183983
- Published: 2025-01-17T15:12:02+00:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** which can be found using ticker (TXG) now have 13 analysts
in total covering the stock. The consensus rating is pointing to ‘buy’. The range
between the high target price and low target price is between $28.00 and $14.00 
and has a mean target at $20.08. Given that the stocks previous close was at $14.98
this would imply there is now a potential upside of 34.0%. There is a 50 day moving
average of $15.10 and the 200 moving average now moves to $20.50. The total market
capitalization for the company now stands at 1.83B. The stock price is currently
at: $15.09 USD

 The potential market cap would be $2,448,238,188 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of $5.26 and
a -11.37% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on: